Chemotherapy of refractory germ cell cancer with Etoposide

J Clin Oncol. 1983 Nov;1(11):706-9. doi: 10.1200/JCO.1983.1.11.706.

Abstract

Eighteen patients with advanced germ-cell cancer (12 primary gonadal, six extragonadal) that was refractory to vinblastine (V), cisplatin (P), and bleomycin (B) were treated with Etoposide (VP-16-213) and cisplatin +/- bleomycin sulfate +/- doxorubicin hydrochloride. All patients experienced nausea, vomiting, alopecia, and myelosuppression. There were no treatment-related deaths. Five (42%) of 12 patients with primary gonadal germ-cell cancer achieved a complete remission and are presently alive with no evidence of disease. None of the six patients with extragonadal germ-cell cancer achieved a complete response. Thirteen patients died 6.2 months (median) after starting Etoposide treatment. Etoposide-containing chemotherapy is useful in patients with primary gonadal germ-cell cancer. Alternative therapies are needed for patients with extragonadal germ cell cancer.

MeSH terms

  • Adolescent
  • Adult
  • Alopecia / chemically induced
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow / drug effects
  • Choriocarcinoma / drug therapy
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Dysgerminoma / drug therapy
  • Etoposide / administration & dosage*
  • Etoposide / adverse effects
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Male
  • Mesonephroma / drug therapy
  • Nausea / chemically induced
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Podophyllotoxin / analogs & derivatives*
  • Retroperitoneal Neoplasms / drug therapy
  • Retroperitoneal Neoplasms / secondary
  • Testicular Neoplasms / drug therapy*

Substances

  • Etoposide
  • Podophyllotoxin
  • Cisplatin